Member Info for Balanced66

Bojo

Do you have any views on Obd?

They do liquid biopsy for predictive medicine and are due to have a covid severity test released shortly and another test later in the year.

They are trying to commercialise their tech which seems highly advanced and protected by patents. Their traditional business of biomarkers has not generated much revenue (biomarker businesses generally don't I understand? Look at Proteome for example).

If these 2 forthcoming tests take off then it will be validation for their tech and can be applied across the board to other disease areas. Initially aiming to sell to the private sector in the US.

Any views from others also appreciated. I have taken a small position and reviewing whether to buy more. I am really impressed with their tech.

Here is a link for more information:

https://www.yellowstoneadvisory.com/post/oxford-biodynamics-webinar-2021-a-year-when-the-technology-will-be-commercialised

My thanks to FekirTrader for this tip.

Having read one of the previous rns's I believe the company are against raising money by issuing new shares. With last years cln rns the company said that the repayment of the cln will be by mutual agreement as to whether it is shares or cash and its intention was to pay in cash! How many companies on Aim have such noble intentions and care for shareholder value?

"The redemption of the Notes can be by way of cash or shares, but the repayment mechanism will be by way of mutual agreement of both parties and the Company is not obliged to issue shares. If shares were to be issued it would be at a 20-day VWAP calculated on the date prior to the repayment date. However, at this stage, the Company intends to repay the Loan Notes in cash. The Notes will be unsecured and rank in subordination to AfriTin's existing working capital facility with Nedbank Namibia."

That's saying a lot about how the company plans to move forward and it seems aligned with shareholder interests from the above statement. Most companies on the Aim are itching for the cln issuer to convert into shares and they are normally converted at a prearranged fixed low or very low share price. How many do VWAP for conversion? I don't recall seeing any lately with VWAP so with the share price of Atm doubled since the cln that's limiting the dilution if they are in fact converted.

Still excellent value imo and a future laid growth plan with nearly all the other pits still left to develop lol!

One important point that may have been missed by people is at 7 minutes and 29 seconds when the CEO talks about the Brandberg West mine and that it is a "similar project there and another multi commodity project there" tin and copper is mentioned and also tantalum (I couldn't hear properly if tantalum was mentioned). The CEO said the market will be updated in future about the Brandberg West mine.

Looks like an inter generational mining project to keep them busy for a very very long time.

Hardwicke

Thanks for your valued input.

Found this link with information on "off label" use:

https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.ouh.nhs.uk/patient-guide/leaflets/files/12048Punlicensed.pdf&ved=2ahUKEwix2cnFr9HuAhXzlFwKHbhTB-EQFjAAegQIARAB&usg=AOvVaw1PhR8FDHtHa6T3KFKVc1G9

Also worth noting that Mxct are also going for a dual listing on Nasdaq later this year which Stifel are probably helping them to do.

Mxct another one of my favourite and main stocks in my pf.

It is a traders share so it may come back?

Risk with these kind of situations is that investors are prepared to put off questions on the fundamentals but sooner or later these questions are asked. So such situations are about timing which I'm not the best at so stay out but others on this board are very good at making the most out of quick trades in and out.

Hopefully will get better at trading a few more over time! But I prefer my approach of buying good quality companies at fair prices. If markets do crash more of a chance of those kind of companies recovering- that's my theory anyway not saying it's right.

But whatever works best for people they should follow that.

Missed that one didn't see it until near/after market close.

A lot of shares in red today including gold miners?

Market pausing for breath?

They haven't mentioned the Lft progress for a while which is odd.

Without Lft they are very early stage biotect valued at over £300m+

Biotechbull

No problem regarding the transcription.

Have to strongly disagree with your interpretation.

That interpretation is not possible because this is word for word what he says about the synthetic sulforaphane:

"We've actually done some experiments with that type of Sulforaphane and found that there are some adverse side effects..."

If he had experimented on Evgen's patented version then he would have said so and Evgen may have released an Rns to say permission has been given to Dr Fahy I'm not aware of any such rns. The permission of the owner is required before such experiments are done. Doesn't sound like a trial was done as Evgen would have announced in an rns so the results of the "experiments" are dubious if not done to clinical trial standards.

You do know that there are synthetic versions available of sulforaphane? However only Evgen has Sulforadex® so not one and the same thing.

I'm no scientist so if you want to learn more read Moneymunch's informative posts.

Fekir mentioned Atm which looks good as well, forecast to increase revenues for next few years; 2022 revenues forecast to be £17.7m. Forecasts do change all the time though. But one of the few smaller mining companies due to start making real turnover.

Bmn still looks really undervalued and with some good newsflow should continue its march upwards.

These comments by Dr Fahey have been taken out of context imo.

Dr Fahey's whole video was about the nutrition side of sulforaphane and foods. In the video he recommends eating a whole food vegetable diet. The discussion is about broccoli etc.

What he then does at 1 hour 29 minutes is talk about the therapeutic medicinal use - two completely different uses. Every medicinal drug has a side effect.

He actually says with that "type " and not "kind". So he has not tested Evgen's version. These may have just been his own experiments and not part of drug trials.

He also says "some adverse side effects " so not many and he doesn't specify what they are.

It's also clear that he has not tested Evgen's formulation as it is patented and is stable which is what he talks about that it is difficult to stabilise. So his comments are just about the non natural state and not as stabilised by Evg and also in the context of comparing it to food use when you would expect there to be "some side effects ". However as others have pointed out the evidence to date shows Sulforadex is well tolerated.

Hope Rms works out for you. These options and warrants seem to be never ending the big money is being made by directors/former directors at moment who have made millions from share sales. Hope this doesn't become a Gdr for you - good products but no sales.

I got a few through HL telephone dealing only.

Bad move to list on Aquis not impressed with that exchange. I think TSP would have fared better on Aim.

I've never done it before buying and selling in a trading range but solg seems to be in one at the moment 32-37/8.

Bought some this morning at 32.41 let's see if trading techniques can work for me. There must be a lot more to it than this like volumes etc as well?

I'm happy to hold long term if the trade doesn't work out as planned.

Trd looks like a good company. Sales nearly double market cap.

Thanks Nolupus. I find it hard to value biotechs like Farn that are yet to pass through all trials from phase 1 to phase 3. There is also the risk of failure of drug programs.

But sometimes there is a lot of value in them and money to be made by trading and/or derisking before readouts like you advised on Sng before the hospital trial readouts last year.

Also a lot of them may be very valuable even though there are still lots of trials to complete etc. If only I had more knowledge and skills to assess such companies properly.

For example, VelosBio Inc. was sold to Merck & Co., Inc., Kenilworth NJ., USA, for cash consideration of $2.75 billion. It is not a listed company and if it had been I would most likely never have invested as would have viewed as too risky or a long time from achieving value as early stage. But such early stage companies still do deals after phase 1/2 and so are worth looking into - note for myself!

Like you say its down to money management and risk and not investing more than you can afford to lose.

In my pf I try to achieve as much certainty as I can but sometimes I feel I'm missing out on the fun that others are having when their stocks are doubling etc in a matter of days.

What's your view on Farn Nolupus? Is it worth holding on to?

I have a small holding in the pension I bought at £4.00ish so good to see it in the blue again from around 40% ish down!

These biotechs are very volatile doubling/increasing, halving and then doubling again from the lows not for the faint hearted.

Yes very quiet board considering that this is one of the best investments out there. I was talking to myself when this was £2 and posted at the time that this company was one of the best stock market investments at the time. Long term that still holds imo as it is a leader in its field and continues to win new business. It will also get royalties from future successful drug launches that other companies are developing but also gets income from all the stages leading up to any successful drug launch. This is without spending millions in drug trials itself; in fact other cell therapy companies need to pay Mxct handsome sums of money to use its equipment but the payments do not stop there. I found this fascinating that others will fund and do the development and pay Mxct for its equipment and then also royalties!

Genomics has been flagged as a future growth area and Mxct has a share in a lot of the drug development programmes of the leading genomics companies in the world.

I have not seen another business model (but there may be such other companies - if there are pease let me know!) like this and/or available for this valuation.

Hopefully the forthcoming Nasdaq listing will start to align the valuation with the US companies valued in the billions.

Nearly all or if not all miners have delayed on their timelines since covid. Can anyone let me know of a miner(s) where there have not been delays and the initial deadline/expected date for the joint venture has been met?

I'm still waiting for the deal in aau and other shares i have observed such as bmv, krs, kat etc have all been delayed.

At least we are still talking and hopeful of concluding.

https://www.theguardian.com/technology/2021/jan/12/in-bits-the-programmer-locked-out-of-his-130m-bitcoin-account

Think I'll stick to gold and other forms of assets.

Good to hear from you again Scoredagainsteps. Agree it is a well run company.

With the expected Chronocort approval the business will become completely derisked from my point of view and onwards and upwards from there.

Hunsen, there has been some dilution since the 2018 200p+ highs. However, we have had further significant progress of the drug programmes since then and we have Ditest as a potential future drug within the next few years hopefully which we did not have in 2018 so the fundamentals are much improved from the old highs.

So all good reasons for upward momentum to continue and the old highs eventually being exceeded.

Gla.

Genericname

A lot of shares (if not most on aim?) are not really long term holdings. In those types of companies it's sensible to take good profits if you have them as they are mostly pump and dump or "trendy" shares that are in fashion.

Companies like Polx are long term growth holdings and the most gains are achieved by compounding the gains.

Here is a link to an article I posted on another board which proves this buy and hold strategy provided the company you invest in for the long term is worthy of holding for the long term based on quality of business, competitive advantage etc. I found this article useful to consider at times like this - he still holds the giants of today from the early days. I have to admit that even I would most likely have sold a lot of those along the way if I held them when he did but investing is a learning process and I hope to get better over time. Not sure if the Forbes link will work so posted another also.

https://www.forbes.com/sites/maddieberg/2019/02/19/the-greatest-investor-youve-never-heard-of-an-optometrist-who-beat-the-odds-to-become-a-billionaire/?sh=14d6d3ca22e8

https://www.google.com/amp/s/www.nasdaq.com/articles/secrets-greatest-investor-youve-never-heard-2019-04-17%3famp